# Veradermics Incorporated (MANE) fundamentals

Data as of 2026-11-04. NYSE, United States. Sector: Healthcare / Biotechnology. Price $133.61, market value $5.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Veradermics Incorporated reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 6.9×**. The shares trade at 6.9× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -1.2%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: 57.8%**. A 57.8% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.

## Growth
- **EPS growth (1 yr): -202.1%**. Earnings per share fell 202.1%.

## Financial health
- **Current ratio: 16.66** (quick 16.66). Current assets cover the next year's liabilities 16.66 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Veradermics Incorporated does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (6 analysts). 6 analysts cover Veradermics Incorporated; the consensus is strong_buy, with an average price target of $170.50 (+28% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **From 52-week high: -8.8%** (317.5% above the low). Trading 9% below its 52-week high.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 1.03** (volatility 92%). Beta of 1.03 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MANE · Page: https://foliofundamentals.com/stocks/mane

Not investment advice.